【高盛：科伦博泰生物(06990.HK)sac-TMT联合疗法临床研究达主要终点 维持“买入”评级】智通财经APP获悉，高盛发布研报称，上调科伦博泰生物(06990.HK)2027及2028年每股盈利预测至7.51元及14.46元人民币，目标价由561.4港元上调至582.95港元，维持“买入”评级，认为科伦博泰有望成为具影响力的全球ADC药企。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.